SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD

NCT02013375 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease

Interventions

PROCEDURE: Haploidentical Transplant
DRUG: Alemtuzumab
RADIATION: Total Body Irradiation
DRUG: Cyclophosphamide
DRUG: Sirolimus

Sponsor

Damiano Rondelli, MD